Member Info for CauldStream7

Hi Alexsnowdenn,

Thanks for calling out Nolupus for what he(or she) is. He pretends to be highly knowledgeable about the P140 drug platform but really he knows nothing about them.

I used to send my comments about Immupharma to a different bulletin board (ADVFN, I think), but left it because of exasperation with the constant negative observations of Nolupus.

He or she never refers to the scientific knowledge of Prof. Muller and Dr Goudreau which underpins the P140 drugs. Why?

Several years ago, in a post to the bulletin board, I commented that the answer to that question might be contained in the pseudonym "Nolupus". He failed to answer. So I'll answer myself.

I think that he does not believe in the existence of Lupus as a disease. If he believes in anything, it is that Lupus is merely a group of symptoms that may be caused by different illnesses, ie a syndrome, that are unrelated. So he may hold to the view that it is a lost cause to look for a drug to cure it.

Nolupus and a few others have tried of late to move the discussion from the time scale for arranging a deal with a powerful and well funded Pharma company, possibly one of the Top 10, to a discussion of how long it will take to conclude a Phase 3 FDA trial. One, two or three years?

That's a discussion that does not greatly concern me. As far as I am aware, negotiations are still progressing to do a deal with one of these large Pharmas, and my concern is how soon this will be tied up.

The responsibility to prove the efficacy of the P140 platform of drugs will then have moved to the large Pharma company which will by that time have bought the rights from Immupharma to commercialise these drugs. I don't believe that it is of consequence to Immupharma shareholders how long this will take except that it will make a difference if the terms of the deal involve stage payments that are linked to future sales.

I don't know where all the numbers come from which are used to estimate the share price at which a deal will be fixed.

Earlier this month, OTM was suggesting a maximum price of 20p per IMM share for a deal. Now, his/her opinion is that it will be 2 or 3 times the current price - I guess he means a price of 25 to 30p. Still very conservative.

For my part, I still abide by the estimate of Seb Goudreau and others who are fully in touch with the science of P140 and where that leaves us as far as the treatment of Autoimmune diseases is concerned. Although this may cause mirth amongst those who are peddling a price of 65p (why?) I'm still staying with a price in pounds, not pence - ie. from £20+

Xviolet: "inexperienced inverters".

I presume you mean "inexperienced investors"?

The science of the P140 drugs has been explained following the patent application last September. I thought it was quite clear without any ambiguity.

I just don't understand why some posters are determined to ignore the scientific findings of Seb Goudreau and his colleagues who have made further discoveries about P140 and its mechanism of action. Also of its new pharmaceutical and diagnostic properties. Why?

In the previous 3 to 4 years I have been steadily buying substantial numbers of IMM shares and I am already well in the money. I feel sure that in the next

few months my profits will continue to improve greatly. And as I've advised already, you can share in these profits but only if you BUY, particularly while the SP is in single figures.

Ogm and others;

I think it is getting through to investors in IMM that the silence denotes work going on behind the scenes between their scientists and those of other Pharmas on the details of the P140 drugs and their implications for the treatment of autoimmune diseases. It takes time to discover what this is going to mean financially for the companies who hold the commercial rights to these drugs.

So it is not unreasonable to wait until March, or even longer, for deals to be worked out and communicated to us.

In the meantime, It makes good sense to BUY while the shares are still costing single figures.

J Kemp;

Incanthera definitely NOT looking good.I'm so glad I have not invested much there.

It is unreasonable to expect Immupharma to issue information on its negotiations with other Pharma companies until they are well advanced.

In the present case, we can probably expect an announcement on what stage has been reached and some outline of the deal that has emerged, in March. That is about 6 months after Immupharma notified us of the filing of patents for the P140 drugs which is not that long a period given their complexity.

Let us have some patience and give Tim McC time to put a statement together which will tell us where we stand a regards a deal. 6 months should provide him with sufficient time to tell us that Immupharma is en route to a great deal.

Aberdeenshire

When Lisa uses the phrase (in the near future) I think she does mean within a week or two otherwise she would be guilty of telling a porkie.

But she also has to battle the scientists on IMM's team who want to be able to dot i's and cross t's before saying anything in public. So I will be awfully disappointed if Tim McC fails to come up with a RNS next week.

I've already bought 6.4 million IMM shares and will probably not buy more because lots of people think I have gone overboard with my purchases.

There are 2 points to keep in mind. The first is that Immupharma's Chief Scientific Officer has stated that he and his research team have discovered more than they ever thought possible in terms of the method of action of the P140 platform of drugs and particularly requiring their use in much higher dosage rates than they thought advisable previously, and secondly, the discovery that these drugs have diagnostic capabilities. Too good to be true? That's obviously what a lot of investors believe.

So now, Goudreau and his team have to convince potential investors that these discoveries are for real. It may be that the task of convincing the doubtful amongst scientists in other Pharma companies will take until March, or longer.

It will be up to Tim, our CEO, to explain to us what us going on without provoking some of us into harsh criticism. Personally I don't think this criticism is at all helpful (I'm not used to this in the village where I live in the North of Scotland). For further information, it helps to contact Lisa Baderoon who is a substantial shareholder as well as being the NED responsible for investor affairs. I think our science is so advanced that a real breakthrough has been made by our science team and that we are very likely to see an announcement on this within the next 2 months. This will mean a very substantial increase in the share price.

In the absence of news, there is nowhere for the SP to go but down. It will be reversed in the twinkle of an eye as soon as Tim announces some news, preferably a strong indication of a deal on the horizon.

Halfbutt and others.

I bought 6.4 million shares , the first of these in 2009. But I went wild with my purchases when the Immupharma share price collapsed, despite Avion reaching an agreement to support a new P3 Trial of Lupuzor/P140. Over a 2 to 3 year period I bought large numbers of IMM shares at prices between 1.1 and 3 pence. That enabled me to average down my shares' price to under 4p. If I were to sell these Immupharma I would be left with a profit, but I don't want to do so until after Immupharma completes a deal with a large Pharma company.

My expectation is that a deal will encompass the commercialisation of several effective anti- autoimmune drugs each of which will have very large market. Their worth will go well beyond a few pennies per share. As IMM's Chief Scientific Officer has said, this will go well beyond what seems believable.

There is now a real prospect of missing out on a huge return for private investors like us, unless we act soon.

I've read the Hardman Report, and particularly page 8 which shows that Immupharma has the best financial record of all small R and D pharma companies. I think this will become clearer by the end of this month. By then, we should be reading a RNS from our CEO which will give us some details of the negotiations on a deal with one or more large Pharmas.

In the meantime, I am amazed that Immupharma's share price is stuck around 6-7p. Even the most conservative of the commentators on this board has set a price of 20p for the share price by June, 3 times as great as the present one, a pretty good return.

I have tried to stick with the scientists who have developed Lupuzor/P140, starting with Prof Muller of the French National Research Institute and continuing with Dr Seb Goudreau who has refined the P140 medical capabilities to the point when it has been possible to file patents last September for the P140 drugs with the development of their new diagnostic and therapeutic properties.

I stayed with IMM because I was convinced that Prof Muller and her team would get the next trial right.

Dr Goudreau followed up Prof Muller's work and developed the P140 drugs. I all that time the SP has been in the doldrums until last year when patents for P140 were filed. All that time, I continued to back IMM's shares and to buy their shares at prices between 1 and 3 p. I now have over 6 milliion shares.

So I'm now in profit but there is no way that I will sell the shares now. I truly expect that IMM will end up with a lucrative deal with a large Pharma. Perhaps it will be preceded by an RNS when a deal is near.

I think that the present SP of 6 - 7 p will soon be seen as ridiculously cheap; indeed, that a single figure SP price in pennies will soon be a thing of the past.

I believe we will get an update soon from Tim McC on the negotiations between IMM and the big buddies among the large Pharmas.

Have just read a report on the progress among the small pharmas which put Immupharma ahead of the field.

Hardman-and-Co-Monthly-January-2026.pdf

Tim and the Board will probably be working on a deal as I write. We could get an update from him in a week's time or so via an RNS.

Bobsponge:

I agree with you. The P140 platform provides drugs which are without parallel having both therapeutic as well as diagnostic capabilities which apply to around 50 autoimmune diseases. If what is claimed for these drugs is correct, we are into new treatment territory. No wonder it is possible to think of the price of this bundle being subject to large price movements because many people do not accept these capabilities claimed for them. We are talking about the kind of step change in treatment when penicillin was invented. You have to believe what's written on the tin.

OTM:

You are repeatedly complaining about other contributors to this bb who you allege are being offensive/rude towards you. But who are you? I have tried to find a trace of your name but I can't find it?

Did you invent it? Is it a pseudonym? If there is no such person in existence, how can one be rude to it\him\her?

OTM:

I have read several estimates of the value of IMM from various contributors to this bulletin board.

The lowest of these has been provided by you: 20-30p. You claim this is logical without explaining the logic. It is surely very difficult to judge what is logical price-wise when trying to value P140 with its drugs claimed to have therapeutic as well as diagnostic capabilities in relation to around 50 autoimmune diseases. So, OTM, explain how reach the target of 20-30p.

Other contributors have explained in great detail how they reach a valuation of IMM shares between £5 and over £120. So perhaps you mean to suggest a valuation of £20 instead of 20p?